Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B3
Source: 0001062993-25-010580
Chunk: 196

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B3
Chunk 196
---
 part be declared effective by the SEC and the final form of this prospectus is filed with the SEC. From and after such date, we will have the right, but not the obligation, from time to time, at our sole and exclusive discretion, for the 36-month period after the date of the SEPA, to direct the Selling Shareholder to purchase a specified amount of common shares, not to exceed the greater of: (1) an amount equal to the average of the daily volume traded of the common shares on the five consecutive trading days immediately preceding an Advance Notice (as defined below) and (2) such number of common shares equal to $500,000 as of the date of each Advance Notice, as described further below under the heading "-Advances of Common Shares Under the SEPA."

We will control the timing and amount of any sales of common shares to the Selling Shareholder. Actual sales of common shares to the Selling Shareholder under the SEPA will depend on a variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our common shares, and determinations by us as to the appropriate sources of funding for the Company and its operations.

Under the applicable Nasdaq rules, in no event may we issue to the Selling Shareholder under the SEPA more than 2,362,163 common shares, which number of shares is equal to 19.99% of the aggregate number of common shares issued and outstanding immediately prior to the execution of the SEPA (the "Exchange Cap"), unless (i) we obtain shareholder approval to issue common shares in excess of the Exchange Cap in accordance with applicable Nasdaq rules or (ii) the average price of all applicable sales of common shares under the SEPA equals or exceeds $2.75 per share (which represents the lower of (a) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) immediately preceding the Effective Date; or (b) the average Nasdaq Official Closing Price for the five trading days immediately preceding the Effective Date). Moreover, we may not issue or sell any common shares to the Selling Shareholder under the SEPA which, when aggregated with all other common shares then beneficially owned by the Selling Shareholder and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the Selling Shareholder beneficially owning common shares in excess of the 4.99%